The CF Foundation announced a $15 million research initiative with biopharmaceutical company Shire to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
The multi-year research program will evaluate a new, cutting-edge approach to improve the function of the defective protein associated with cystic fibrosis.
While this research is in its very early stages, the potential therapy is exciting because it is one of several that could benefit all people with cystic fibrosis, regardless of their mutations.
Read more about this exciting news
We still have much to do, but with your support, we will continue to help advance new treatments for all people with the disease. We will not rest until we find a cure.